Orchestra BioMed Holdings, Inc. (OBIO) 10-Year Financial Performance & Capital Metrics

OBIO • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Show more

Revenue $3M -4.4%
EBITDA -$64M -24.9%
Net Income -$61M -24.2%
EPS (Diluted) -1.66 -12.2%
Gross Margin 92.27% -1.1%
EBITDA Margin -2425.82% -30.7%
Operating Margin -2437.49% -30.6%
Net Margin -2313.27% -30.0%
ROE -120.84% -48.3%
ROIC -145.26% -57.5%
Debt/Equity 0.50 +1922.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 10.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-98%

5Y Avg-98%

3Y Avg-78.91%

Latest-89.33%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	5.7M	-782K	3.53M	2.76M	2.64M
Revenue Growth %	-	-1.14%	5.52%	-0.22%	-0.04%
Cost of Goods Sold+	145K	199K	322K	186K	204K
COGS % of Revenue	0.03%	-0.25%	0.09%	0.07%	0.08%
Gross Profit+	5.56M	-981K	3.21M	2.57M	2.43M
Gross Margin %	0.97%	1.25%	0.91%	0.93%	0.92%
Gross Profit Growth %	-	-1.18%	4.27%	-0.2%	-0.05%
Operating Expenses+	24.31M	20.82M	35.87M	54.08M	66.73M
OpEx % of Revenue	4.26%	-26.62%	10.15%	19.59%	25.3%
Selling, General & Admin	10.83M	7.93M	13.92M	20.26M	23.93M
SG&A % of Revenue	1.9%	-10.14%	3.94%	7.34%	9.07%
Research & Development	13.48M	12.89M	21.95M	33.82M	42.8M
R&D % of Revenue	2.36%	-16.48%	6.21%	12.25%	16.23%
Other Operating Expenses	0	0	0	0	0
Operating Income+	-18.75M	-21.8M	-32.66M	-51.51M	-64.3M
Operating Margin %	-3.29%	27.88%	-9.24%	-18.66%	-24.37%
Operating Income Growth %	-	-0.16%	-0.5%	-0.58%	-0.25%
EBITDA+	-18.61M	-21.62M	-32.44M	-51.22M	-63.99M
EBITDA Margin %	-3.26%	27.64%	-9.18%	-18.56%	-24.26%
EBITDA Growth %	-	-0.16%	-0.5%	-0.58%	-0.25%
D&A (Non-Cash Add-back)	137K	181K	222K	287K	308K
EBIT	-18.75M	-21.8M	-32.66M	-51.51M	-64.3M
Net Interest Income+	331K	-927K	50K	3.85M	3.36M
Interest Income	331K	0	50K	3.85M	3.36M
Interest Expense	0	927K	0	0	0
Other Income/Expense	-2.6M	-1.22M	-951K	2.39M	3.28M
Pretax Income+	-21.36M	-23.01M	-33.61M	-49.12M	-61.02M
Pretax Margin %	-3.74%	29.43%	-9.51%	-17.8%	-23.13%
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-21.36M	-23.01M	-33.61M	-49.12M	-61.02M
Net Margin %	-3.74%	29.43%	-9.51%	-17.8%	-23.13%
Net Income Growth %	-	-0.08%	-0.46%	-0.46%	-0.24%
Net Income (Continuing)	-21.36M	-23.01M	-33.61M	-49.12M	-61.02M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.02	-1.32	-1.48	-1.66
EPS Growth %	-	-	-70.35%	-0.12%	-0.12%
EPS (Basic)	-0.01	-0.02	-1.32	-1.48	-1.66
Diluted Shares Outstanding	20.45M	20.45M	25.47M	33.23M	36.82M
Basic Shares Outstanding	20.45M	20.45M	25.47M	33.23M	36.82M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	36.25M	11.32M	84.69M	89.11M	69.17M
Cash & Short-Term Investments	35.79M	10.9M	83.78M	87.59M	66.81M
Cash Only	20.34M	9.94M	19.78M	30.56M	22.26M
Short-Term Investments	15.45M	958K	64M	57.04M	44.55M
Accounts Receivable	168K	121K	96K	99K	92K
Days Sales Outstanding	10.75	-56.48	9.92	13.09	12.73
Inventory	69K	68K	276K	146K	173K
Days Inventory Outstanding	173.69	124.72	312.86	286.51	309.53
Other Current Assets	0	0	533K	1.27M	2.09M
Total Non-Current Assets+	1.84M	2.21M	10.88M	6.1M	7M
Property, Plant & Equipment	1.03M	1.12M	3.68M	2.83M	3.49M
Fixed Asset Turnover	5.55x	-0.70x	0.96x	0.97x	0.76x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	185K	398K	2.5M	2.5M	2.5M
Other Non-Current Assets	626K	690K	4.71M	769K	1.02M
Total Assets+	38.09M	13.53M	95.57M	95.21M	76.17M
Asset Turnover	0.15x	-0.06x	0.04x	0.03x	0.03x
Asset Growth %	-	-0.64%	6.07%	-0%	-0.2%
Total Current Liabilities+	14.36M	12.24M	18.57M	11.21M	16.21M
Accounts Payable	1.77M	2.03M	3.97M	2.9M	5.13M
Days Payables Outstanding	4.47K	3.72K	4.5K	5.69K	9.19K
Short-Term Debt	4M	2M	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.18M	780K	4.57M	2.66M	2.61M
Current Ratio	2.52x	0.92x	4.56x	7.95x	4.27x
Quick Ratio	2.52x	0.92x	4.55x	7.94x	4.26x
Cash Conversion Cycle	-4.28K	-3.65K	-4.18K	-5.39K	-8.86K
Total Non-Current Liabilities+	72.27M	72.52M	24.47M	15.96M	27.01M
Long-Term Debt	5.46M	3.67M	9.49M	0	14.29M
Capital Lease Obligations	0	0	1.68M	1.04M	1.69M
Deferred Tax Liabilities	0	0	0	-14.92M	0
Other Non-Current Liabilities	51.69M	51.99M	196K	14.92M	40K
Total Liabilities	86.63M	84.76M	43.04M	27.17M	43.22M
Total Debt+	9.46M	5.67M	11.87M	1.69M	16.53M
Net Debt	-10.89M	-4.26M	-7.91M	-28.87M	-5.73M
Debt / Equity	-	-	0.23x	0.02x	0.50x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-23.52x	-	-	-
Total Equity+	-48.54M	-71.23M	52.53M	68.04M	32.96M
Equity Growth %	-	-0.47%	1.74%	0.3%	-0.52%
Book Value per Share	-2.37	-3.48	2.06	2.05	0.90
Total Shareholders' Equity	-48.54M	-71.23M	52.53M	68.04M	32.96M
Common Stock	0	160M	2K	4K	4K
Retained Earnings	-143.11M	-166.13M	-199.73M	-248.85M	-309.88M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-2K	-211.45M	-8K	-10K	52K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-26.18M	-19.43M	-29.29M	-46.13M	-50.56M
Operating CF Margin %	-4.59%	24.85%	-8.29%	-16.71%	-19.17%
Operating CF Growth %	-	0.26%	-0.51%	-0.57%	-0.1%
Net Income	-21.36M	-23.01M	-33.61M	-49.12M	-61.02M
Depreciation & Amortization	137K	181K	222K	287K	308K
Stock-Based Compensation	221K	302K	3.41M	7.63M	10.62M
Deferred Taxes	0	288K	0	0	0
Other Non-Cash Items	2.93M	217K	1.14M	-1.61M	308K
Working Capital Changes	-8.12M	2.6M	-451K	-3.31M	-765K
Change in Receivables	-79K	47K	25K	-3K	22K
Change in Inventory	-26K	1K	-208K	131K	-28K
Change in Payables	-2.61M	1.08M	0	145K	2.97M
Cash from Investing+	26.97M	13.02M	-64.12M	10.69M	13.09M
Capital Expenditures	-539K	-274K	-591K	-78K	-289K
CapEx % of Revenue	0.09%	-0.35%	0.17%	0.03%	0.11%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	27.5M	13.29M	0	0	0
Cash from Financing+	10M	-3.99M	103.26M	46.22M	29.17M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-162.29M	7K	-10.13M	56.81M	-864K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-26.72M	-19.7M	-29.88M	-46.2M	-50.85M
FCF Margin %	-4.69%	25.2%	-8.46%	-16.74%	-19.27%
FCF Growth %	-	0.26%	-0.52%	-0.55%	-0.1%
FCF per Share	-1.31	-0.96	-1.17	-1.39	-1.38
FCF Conversion (FCF/Net Income)	1.23x	0.84x	0.87x	0.94x	0.83x
Interest Paid	0	0	1.37M	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-63.97%	-81.47%	-120.84%
Return on Invested Capital (ROIC)	-	-	-	-92.2%	-145.26%
Gross Margin	97.46%	125.45%	90.89%	93.26%	92.27%
Net Margin	-374.45%	2942.97%	-951.26%	-1779.71%	-2313.27%
Debt / Equity	-	-	0.23x	0.02x	0.50x
Interest Coverage	-	-23.52x	-	-	-
FCF Conversion	1.23x	0.84x	0.87x	0.94x	0.83x
Revenue Growth	-	-113.71%	551.79%	-21.88%	-4.42%

Revenue by Segment

	2023	2024
Product	654K	633K
Product Growth	-	-3.21%

Frequently Asked Questions

Growth & Financials

Orchestra BioMed Holdings, Inc. (OBIO) reported $2.6M in revenue for fiscal year 2024. This represents a 54% decrease from $5.7M in 2020.

Orchestra BioMed Holdings, Inc. (OBIO) saw revenue decline by 4.4% over the past year.

Orchestra BioMed Holdings, Inc. (OBIO) reported a net loss of $61.0M for fiscal year 2024.

Dividend & Returns

Orchestra BioMed Holdings, Inc. (OBIO) has a return on equity (ROE) of -120.8%. Negative ROE indicates the company is unprofitable.

Orchestra BioMed Holdings, Inc. (OBIO) had negative free cash flow of $50.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener